Home LiteratureArticle Details
PMID: 19383292 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer.

Molecular oncology ·Vol. 1 ·No. 2 ·2007-09-00 ·Pages 160-71

Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjaerde OC, Strømberg M, Wiedswang G, Kvalheim G, Kåresen R, Nesland JM, Børresen-Dale AL, Sørlie T

Abstract

Expression profiles of primary breast tumors were investigated in relation to disseminated tumor cells (DTCs) in bone marrow (BM) in order to increase our understanding of the dissemination process. Tumors were classified into five pre-defined molecular subtypes, and presence of DTC identified (at median 85 months follow-up) a subgroup of luminal A patients with particular poor outcome (p=0.008). This was not apparent for other tumor subtypes. Gene expression profiles associated with DTC and with systemic relapse for luminal A patients were identified. This study suggests that DTC in BM differentially distinguishes clinical outcome in patients with luminal A type tumors and that DTC-associated gene expression analysis may identify genes of potential importance in tumor dissemination.

MeSH Terms
Adult Bone Marrow Neoplasms/classification,genetics,metabolism,mortality,secondary Breast Neoplasms/classification,genetics,metabolism,mortality Disease-Free Survival Female Follow-Up Studies Gene Expression Profiling Gene Expression Regulation, Neoplastic Humans Middle Aged Neoplasm Metastasis Neoplasm Proteins/biosynthesis,genetics Retrospective Studies Risk Factors Survival Rate
Chemicals
Neoplasm Proteins
Authors & Affiliations
13 authors, click to expand affiliations / ORCID
Naume Bjørn
Cancer Clinic, Rikshospitalet-Radiumhospitalet Medical Centre, Montebello 0310, Oslo, Norway.
Zhao Xi
Synnestvedt Marit
Borgen Elin
Russnes Hege Giercksky
Lingjaerde Ole Christian
Strømberg Maria
Wiedswang Gro
Kvalheim Gunnar
Kåresen Rolf
Nesland Jahn M
Børresen-Dale Anne-Lise
Sørlie Therese
References (52)
52 references, click to expand
  1. Chips to bedside: incorporation of microarray data into clinical practice.
    Clin Cancer Res. 2006 Dec 15;12(24):7209-14 PMID: 17189391
  2. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.
    N Engl J Med. 2000 Feb 24;342(8):525-33 PMID: 10684910
  3. Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements.
    Mol Endocrinol. 1995 Jul;9(7):794-804 PMID: 7476963
  4. Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells.
    Cytotherapy. 1999;1(5):377-88 PMID: 20426539
  5. Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF.
    Ann Oncol. 2005 May;16(5):743-8 PMID: 15802278
  6. The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3beta and cAMP-responsive element-binding protein-dependent pathways.
    J Biol Chem. 2000 Oct 20;275(42):32649-57 PMID: 10915780
  7. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
    Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 PMID: 16199517
  8. Cluster analysis and display of genome-wide expression patterns.
    Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 PMID: 9843981
  9. SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data.
    Nucleic Acids Res. 2003 Jan 1;31(1):219-23 PMID: 12519986
  10. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
    Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 PMID: 11553815
  11. Molecular signature associated with bone marrow micrometastasis in human breast cancer.
    Cancer Res. 2003 Sep 15;63(18):5679-84 PMID: 14522883
  12. Mutation screening of the TP53 gene by temporal temperature gradient gel electrophoresis.
    Methods Mol Biol. 2005;291:207-16 PMID: 15502225
  13. A progression puzzle.
    Nature. 2002 Aug 22;418(6900):823 PMID: 12192390
  14. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers.
    Cancer Res. 2004 Jan 1;64(1):64-71 PMID: 14729609
  15. Inhibition of the Wnt signaling pathway by Idax, a novel Dvl-binding protein.
    Mol Cell Biol. 2001 Jan;21(1):330-42 PMID: 11113207
  16. Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations.
    Clin Cancer Res. 2004 Aug 15;10(16):5508-17 PMID: 15328190
  17. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer.
    J Clin Oncol. 2003 Sep 15;21(18):3469-78 PMID: 12972522
  18. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.
    Lancet. 2003 Aug 2;362(9381):362-9 PMID: 12907009
  19. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
    Cancer Res. 2001 Mar 15;61(6):2505-12 PMID: 11289122
  20. Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics.
    Clin Cancer Res. 2001 Dec;7(12):4122-9 PMID: 11751511
  21. Breast cancer classification and prognosis based on gene expression profiles from a population-based study.
    Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 PMID: 12917485
  22. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival.
    Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3738-43 PMID: 15701700
  23. Evaluation of gene expression measurements from commercial microarray platforms.
    Nucleic Acids Res. 2003 Oct 1;31(19):5676-84 PMID: 14500831
  24. Repeated observation of breast tumor subtypes in independent gene expression data sets.
    Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 PMID: 12829800
  25. The IARC TP53 database: new online mutation analysis and recommendations to users.
    Hum Mutat. 2002 Jun;19(6):607-14 PMID: 12007217
  26. A molecular signature of metastasis in primary solid tumors.
    Nat Genet. 2003 Jan;33(1):49-54 PMID: 12469122
  27. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
    J Natl Cancer Inst. 2006 Apr 5;98(7):472-82 PMID: 16595783
  28. Proteomic analysis of rat liver peroxisome: presence of peroxisome-specific isozyme of Lon protease.
    J Biol Chem. 2004 Jan 2;279(1):421-8 PMID: 14561759
  29. Gene expression profiling predicts clinical outcome of breast cancer.
    Nature. 2002 Jan 31;415(6871):530-6 PMID: 11823860
  30. Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma.
    Br J Cancer. 2005 Oct 17;93(8):939-45 PMID: 16189522
  31. Outcome signature genes in breast cancer: is there a unique set?
    Bioinformatics. 2005 Jan 15;21(2):171-8 PMID: 15308542
  32. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients.
    Nat Med. 1996 Jul;2(7):811-4 PMID: 8673929
  33. Prospective identification of tumorigenic breast cancer cells.
    Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 PMID: 12629218
  34. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study.
    Lancet. 1999 Jul 17;354(9174):197-202 PMID: 10421301
  35. Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer.
    Mol Oncol. 2007 Sep;1(2):160-71 PMID: 19383292
  36. A pooled analysis of bone marrow micrometastasis in breast cancer.
    N Engl J Med. 2005 Aug 25;353(8):793-802 PMID: 16120859
  37. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
    Clin Cancer Res. 2004 Oct 1;10(19):6622-8 PMID: 15475452
  38. beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis.
    Cancer Res. 2006 Sep 15;66(18):9108-16 PMID: 16982753
  39. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer.
    Cancer Res. 2005 Mar 15;65(6):2170-8 PMID: 15781628
  40. Gene expression profiles of human breast cancer progression.
    Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9 PMID: 12714683
  41. Prognostic relevance of gene amplifications and coamplifications in breast cancer.
    Cancer Res. 2004 Dec 1;64(23):8534-40 PMID: 15574759
  42. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.
    J Clin Oncol. 2004 Jun 15;22(12):2284-93 PMID: 15136595
  43. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors.
    J Clin Oncol. 2001 Feb 15;19(4):960-71 PMID: 11181658
  44. A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples.
    Mol Pathol. 2003 Oct;56(5):275-9 PMID: 14514921
  45. Significance analysis of microarrays applied to the ionizing radiation response.
    Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 PMID: 11309499
  46. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer.
    Cancer Res. 1987 Nov 15;47(22):6126-33 PMID: 3664512
  47. Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion.
    J Natl Cancer Inst. 2004 Jun 16;96(12):956-65 PMID: 15199115
  48. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.
    J Natl Cancer Inst. 1996 Nov 20;88(22):1652-8 PMID: 8931609
  49. Optimization and evaluation of T7 based RNA linear amplification protocols for cDNA microarray analysis.
    BMC Genomics. 2002 Oct 30;3(1):31 PMID: 12445333
  50. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients.
    Cancer Res. 2005 May 15;65(10):4059-66 PMID: 15899795
  51. Gene expression profiles of primary breast tumors maintained in distant metastases.
    Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15901-5 PMID: 14665696
  52. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.
    BMC Genomics. 2006 May 26;7:127 PMID: 16729877
Article Info
Journal
Molecular oncology
Abbr.
Mol Oncol
ISSN
1878-0261
DOI
10.1016/j.molonc.2007.03.004
Published
2007-09-00
Epub
2007-00-04
Pages
160-71
Language
English
Region
United States
NLM ID
101308230
PMCID
PMC5543886
Subset
IM
Corrections
ErratumIn
-
External Links
PubMed source DOI: 10.1016/j.molonc.2007.03.004 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2